Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ELTX

Elicio Therapeutics (ELTX) Stock Price, News & Analysis

Elicio Therapeutics logo

About Elicio Therapeutics Stock (NASDAQ:ELTX)

Advanced Chart

Key Stats

Today's Range
$8.19
$9.03
50-Day Range
N/A
52-Week Range
N/A
Volume
43,283 shs
Average Volume
57,512 shs
Market Capitalization
$92.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Moderate Buy

Company Overview

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

Elicio Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
28th Percentile Overall Score

ELTX MarketRank™: 

Elicio Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 817th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Elicio Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Elicio Therapeutics has received no research coverage in the past 90 days.

  • Read more about Elicio Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Elicio Therapeutics are expected to grow in the coming year, from ($3.89) to ($3.62) per share.

  • Price to Book Value per Share Ratio

    Elicio Therapeutics has a P/B Ratio of 6.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.73% of the float of Elicio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Elicio Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Elicio Therapeutics has recently increased by 2.68%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Elicio Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Elicio Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.73% of the float of Elicio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Elicio Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Elicio Therapeutics has recently increased by 2.68%, indicating that investor sentiment is decreasing.
    • Insider Buying vs. Insider Selling

      In the past three months, Elicio Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      28.65% of the stock of Elicio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      Only 35.03% of the stock of Elicio Therapeutics is held by institutions.

    • Read more about Elicio Therapeutics' insider trading history.
    Receive ELTX Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Elicio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    ELTX Stock News Headlines

    DOGE To DO List
    Elon's found so much waste he's now claiming "the magnitude of the fraud in federal entitlements" is greater than "the combined sum of every private scam you've ever heard by FAR"... And while this is disturbing and even infuriating to see our tax money literally wasted... there IS a solution. I believe it's Elon's ultimate end game.
    See More Headlines

    ELTX Stock Analysis - Frequently Asked Questions

    Elicio Therapeutics, Inc. (NASDAQ:ELTX) announced its earnings results on Tuesday, August, 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.96) by $0.32.

    Elicio Therapeutics (ELTX) raised $40 million in an initial public offering on the week of July 26th 2021. The company issued 3,100,000 shares at a price of $12.00-$14.00 per share. BTIG and Oppenheimer & Co,. acted as the underwriters for the IPO and National Securities Corp. was co-manager.

    Top institutional shareholders of Elicio Therapeutics include CM Management LLC (0.37%).
    View institutional ownership trends
    .

    Based on aggregate information from My MarketBeat watchlists, some other companies that Elicio Therapeutics investors own include Atreca (BCEL), Cytokinetics (CYTK), Datadog (DDOG), First Solar (FSLR), Intuitive Surgical (ISRG), Moderna (MRNA) and NVIDIA (NVDA).

    Company Calendar

    Last Earnings
    8/13/2024
    Today
    2/23/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    N/A
    Current Symbol
    NASDAQ:ELTX
    Fax
    N/A
    Employees
    N/A
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $10.00
    High Stock Price Target
    $10.00
    Low Stock Price Target
    $10.00
    Potential Upside/Downside
    +17.1%
    Consensus Rating
    Moderate Buy
    Rating Score (0-4)
    2.50
    Research Coverage
    2 Analysts

    Profitability

    Net Income
    $-35,190,000.00
    Pretax Margin
    N/A

    Debt

    Sales & Book Value

    Annual Sales
    $2.30 million
    Book Value
    $1.35 per share

    Miscellaneous

    Free Float
    7,699,000
    Market Cap
    $92.15 million
    Optionable
    Not Optionable
    Beta
    0.77
    (Almost)  Everything You Need To Know About The EV Market Cover

    Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

    Get This Free Report

    This page (NASDAQ:ELTX) was last updated on 2/24/2025 by MarketBeat.com Staff
    From Our Partners